Document 0814
 DOCN  M94B0814
 TI    Correlation between response to acyclovir and foscarnet therapy and in
       vitro susceptibility result for isolates of herpes simplex virus from
       human immunodeficiency virus-infected patients.
 DT    9412
 AU    Safrin S; Elbeik T; Phan L; Robinson D; Rush J; Elbaggari A; Mills J;
       Department of Medicine, University of California, San Francisco; 94143.
 SO    Antimicrob Agents Chemother. 1994 Jun;38(6):1246-50. Unique Identifier :
       AIDSLINE MED/94379774
 AB    In vitro susceptibility testing of herpes simplex virus (HSV) isolates
       will play an increasingly important role in guiding the clinical
       management of immunocompromised hosts who have lesions that are poorly
       responsive to therapy with standard antiviral agents. We assessed the
       correlation between the in vitro susceptibility result using a plaque
       reduction assay in Vero cells and the response to antiviral therapy with
       acyclovir or foscarnet for 243 clinical isolates of HSV collected from
       115 human immunodeficiency virus-infected patients. The in vitro results
       and clinical responses were highly associated for both acyclovir and
       foscarnet (P < 0.001 and P < 0.001, respectively). The predictive values
       of a susceptible result (50% effective concentrations, < 2 micrograms/ml
       for acyclovir and < 100 micrograms/ml for foscarnet) for complete
       healing of lesions were 62% for acyclovir and 82% for foscarnet; the
       predictive values of a resistant result for failure to heal were 95% for
       acyclovir and 88% for foscarnet. Thus, in vitro testing has clinical
       utility in guiding therapy, although the 1 to 2 weeks required to derive
       a definitive result by the plaque reduction assay is a major limitation.
 DE    Acyclovir/*PHARMACOLOGY/THERAPEUTIC USE  Female
       Foscarnet/*PHARMACOLOGY/THERAPEUTIC USE  Herpes Simplex/*DRUG THERAPY
       Human  HIV Infections/*MICROBIOLOGY  Male  Microbial Sensitivity Tests
       Simplexvirus/*DRUG EFFECTS  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).